Pfizer divests USD 3.5 billion stake in Haleon
Advertisement
Sensodyne-marker Haleon has said that Pfizer, its top shareholder, divested approximately a $3.5 billion stake in the consumer healthcare firm, reducing its ownership in the British company to 22.6%. Previously, Pfizer held a 32% stake, while the second-largest shareholder, GSK, held a 4.2% stake.
This marks Pfizer's first stake sale in Haleon since the company's inception in 2022, following its spin-off from GSK and subsequent listing. Last year, Pfizer announced its intention to gradually decrease its ownership in a "slow and methodical" manner over the course of months.
Read also: GSK raises USD 1.24 billion from latest Haleon stake sale
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.